Ascentage Pharma Group International (AAPG)
$15.06-1.63%Close
SELLCRISIS · day 1
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $350M
- Beta
- 0.66
- P/E (TTM)
- -6.45
- Short % float
- 0.14%
- Days to cover
- 1.5
- SI change
- -53.4%
- 1W
- -6.40%
- 1M
- -8.23%
- vs SPY 1W
- -6.26%
- vs SPY 1M
- -10.73%
Industry peers
FMP comparable companies · ranked by market cap
- TNGXSELLTango Therapeutics, Inc.$3.9BRECOVERYQ 23$23.81-8.07%
- IDYASELLIDEAYA Biosciences, Inc.$3.4BBEARQ 25$36.11-4.99%
- ZLABSELLZai Lab Limited$2.8BCRISISQ 8$24.99-6.06%
- NRIXSELLNurix Therapeutics, Inc.$2.3BBEARQ 11$22.35-0.14%
- NUVBSELLNuvation Bio Inc.$1.7BCRISISQ 4$5.00-3.67%
- ANLSELLAdlai Nortye Ltd.$829MCRISISQ 10$15.62-17.30%
- AVBPSELLArriVent BioPharma, Inc.$779MCRISISQ -6$16.73-2.25%
- VSTMBUYVerastem, Inc.$736MRECOVERYQ 4$8.38-9.70%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
ANALYST & RATINGS
LOADING…Loading analyst data…
Company news
FAQ
- What is LOPJLB’s current signal on AAPG?
- LOPJLB’s latest quantitative signal on Ascentage Pharma Group International (AAPG) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is AAPG in?
- Ascentage Pharma Group International (AAPG) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Ascentage Pharma Group International (AAPG) do?
- Based in Suzhou, China, Ascentage Pharma Group International is a biotechnology firm primarily focused on clinical-stage development. The company is dedicated to discovering and advancing therapeutic solutions for a range of medical conditions, including various cancers, chronic hepatitis B virus (HBV) infections, and age-related ailments. A cornerstone of its product pipeline is HQP1351, a BCR…